CVE-2021-33022Philips Vue PACS Cleartext Transmission of Sensitive Information
Updated under an hour ago ()
Does this affect you?
It affects Philips Vue PACS and 5 other products. Add what you run to find out whether that includes you.
EPSS puts the chance of exploitation in the next 30 days at 0.64%, higher than 50% of scored CVEs.
Do this next
Free account, 1 product
Philips Vue PACS versions 12.2.x.x and prior transmits sensitive or security-critical data in cleartext in a communication channel that can be sniffed by unauthorized actors.
- CVSS
- 7.5 HIGH (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
- Weakness (CWE)
- CWE-319
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- 0.64% (percentile 50)
- Assigned by
- icscert
- NVD analysis
- Modified
- Record last updated
- Apr 16, 2025
- First seen by InfoSec Signals
- Oct 12, 2026
Affected products
Philips Vue PACS philips:vue_pacs (from the name) | from unspecified through 12.2.x.x | CNA record |
Philips Vue MyVue philips:vue_myvue (from the name) | from unspecified through 12.2.x.x | CNA record |
Philips Vue Speech philips:vue_speech (from the name) | from unspecified through 12.2.x.x | CNA record |
Philips Vue Motion philips:vue_motion (from the name) | from unspecified through 12.2.1.5 | CNA record |
philips myvue philips:myvue | before 12.2.1.5 | NVD |
philips speech philips:speech | before 12.2.8.0 | NVD |
philips vue_motion philips:vue_motion | before 12.2.1.5 | NVD |
philips vue_pacs philips:vue_pacs | before 12.2.8.0 | NVD |
References
- https://www.cisa.gov/uscert/ics/advisories/icsma-21-187-01x-refsource-confirm, mitigation, third-party-advisory, us-government-resource
- http://www.philips.com/productsecurityx-refsource-confirm, vendor-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.